Memorial Hermann to Offer Home Infusion Therapy for Patients with Chronic ConditionsHOUSTON, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Memorial Hermann Health System – a nonprofit health system committed to creating healthier Houston communities – has established a services agreement with KabaFusion to provide home infusion therapy for patients with chronic conditions and for those who need intravenous immunoglobulin (IVIG) treatment. Home infusion therapy allows a patient to receive intravenous medication in the convenience of their home instead of having to travel to the hospital.
KabaFusion Acquires Infusion Care Assets from Coram® to Expand its Nationwide Footprint of Patient-Focused ServicesExpansion to Increase KabaFusion’s Footprint to 32 Specialty Pharmacies and 19 Ambulatory Infusion Suites Across 26 States
KabaFusion Selected by GC Biopharma USA, Inc. as a Limited Distribution Partner for Partner of ALYGLO™ for Adults With Primary Humoral Immunodeficiency (PI)CERRITOS, Calif. and LEXINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- KabaFusion, a nationally recognized leader in home infusion, has been selected by GC Biopharma USA, Inc. as a limited distribution partner to provide ALYGLO™ (Immune Globulin Intravenous, Human-stwk) 10% Liquid for Adults, 17 years and older, with Primary Humoral Immunodeficiency (PI). ALYGLO is a liquid solution containing 10% immunoglobulin G (100 mg/mL) for intravenous infusion. ALYGLO uses its novel proprietary Cation Exchange Chromatography (CEX) in the manufacturing process for removing FXIa to undetectable levels. Please see the Full Prescribing Information for ALYGLO™.
KabaFusion Selected by UCB as a Limited Distribution Partner for RYSTIGGO® (rozanolixizumab-noli)CERRITOS, Calif. and LEXINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- KabaFusion, a nationally recognized leader in home infusion, has been selected by UCB as a limited distribution partner to provide RYSTIGGO® (rozanolixizumab-noli). RYSTIGGO® (rozanolixizumab-noli) is for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. It is the only FDA-approved treatment in adults for both anti-AChR and anti-MuSK antibody-positive gMG, the two most common subtypes of gMG.1 For more information, please see the Full Prescribing Information for RYSTIGGO®.
Memorial Hermann Health System Joins Existing Investors in KabaFusion, a Leading National Home Infusion ProviderHOUSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Memorial Hermann Health System (“Memorial Hermann”) – a non-profit, community-focused, award-winning health system committed to creating healthier Greater Houston communities – has co-invested in KabaFusion (the “Company”), a leading national provider of home infusion therapies.
